Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013001507 - TREATMENT PLANNING BASED ON POLYPEPTIDE RADIOTOXICITY SERUM MARKERS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

What is claimed is:

1. A method, comprising:

at least one of creating or adapting a treatment plan for a patient based on a set of serum polypeptides of the patient that are indicative of a radiotoxicity of the patient at least one of before or after at least one of a plurality of radiotherapy treatments of the treatment plan, wherein the radiotoxicity is induced by radiation exposure from the radiotherapy treatment.

2. The method of claim 1, further comprising:

determining masses of polypeptides in a serum sample of the patient;

comparing the determined masses with a pre-determined set of masses of interest; identifying at least one polypeptide having a mass that satisfies the pre-determined set of masses of interest; and

including only the identified polypeptides in the set of polypeptide radiotoxicity bio-markers.

3. The method of claim 2, further comprising:

determining the masses using mass spectrometry.

4. The method of claims 1, further comprising:

determining masses of polypeptides in a serum sample of the patient using an immunoassay.

5. The method of any of claims 1 to 4, further comprising:

determining peak intensities, concentrations or amounts of the polypeptides in the set of polypeptide radiotoxicity serum markers;

comparing the determined peak intensities with threshold intensities corresponding to higher radiosensitivity and lower sensitivity; and

one of classifying the patient as having higher radiosensitivity in response to a predetermined combination of the peak intensities mapping to the intensities corresponding to the higher radiosensitivity, or classifying the patient as having lower radiosensitivity in response to the pre-determined combination of the peak intensities mapping to the intensities corresponding to the lower radiosensitivity.

6. The method of claim 5, further comprising:

identifying a sub- set of treatments from a plurality of treatments for the treatment plan based on the classification of the patient.

7. The method of claim 6, wherein the sub-set of treatments includes one or more of external beam radiotherapy, brachytherapy, surgery, chemotherapy, particle therapy, high intensity focused ultrasound, ablation, cryotherapy, watchful waiting or hormonal therapy.

8. The method of any of claims 6 to 7, further comprising:

visually presenting the identified sub-set of treatments; and

including the presented identified sub-set of set of treatments in the treatment plan in response to receiving an input indicative of user acceptance of the presented identified sub- set of treatments.

9. The method of any of claims 6 to 7, further comprising:

automatically including the presented identified sub-set of treatments in the treatment plan.

10. The method of any of claims 6 to 9, wherein the radiotoxicity represents a radiotoxicity after at least one radiotherapy treatment and before at least another radiotherapy treatment, and further comprising:

creating a personalized treatment plan for the patient based on a predicted radiotoxicity of the patient.

11. The method of any of claims 6 to 9, wherein the radiotoxicity represents a radiotoxicity after at least one radiotherapy treatment, and further comprising:

adapting the treatment plan to personalize the treatment plan for the patient based on a current radiotoxicity of the patient.

12. The method of any of claims 6 to 11, further comprising:

optimizing treatment parameters for one or more treatments of the treatment plan based on the polypeptide radiotoxicity bio-markers.

13. The method of claim 12, further comprising:

adding an extra dose boost to a target volume of a radiotherapy treatment of the treatment plan of an individual patient who has lower radiosensitivity.

14. The method of any of claims 12 to 13, further comprising:

leaving out an extra dose boost to the target volume of the radiotherapy treatment of the treatment plan of a patient with higher radiosensitivity.

15. The method of any of claims 12 to 14, further comprising:

at least one of increasing a predetermined maximum dose of tissue of interest in response to a low predicted or measured toxicity of the tissue of interest or decreasing a predetermined maximum dose of tissue of interest in response to a high predicted or measured toxicity of the tissue of interest.

16. The method of any of claims 12 to 14, further comprising:

modifying a dose distribution contour based on the predicted or measured toxicity of the tissue of interest.

17. The method of any of claims 15 to 16, wherein the tissue of interest includes at least one of the urethra, bladder, bowel, or rectum.

18. The method of any of claims 1 to 17, wherein the polypeptide masses of the set of polypeptide radiotoxicity bio-markers include masses from a group consisting of 11,668 +23Da, 2,876 +6 Da, 6,432 +13 Da, 9,125 +18 Da, 2,220 +4 Da, 9,414 +19 Da and 14,571 +29 Da.

19. A system, comprising:

a treatment planning device (108) that facilitates at least one of creating or adapting a treatment plan for a patient based on amounts or concentrations of a set of serum polypeptides of the patient that indicate a high risk of or an early radiotoxicity of the patient to radiation from radiotherapy.

20. The system of claim 19, the treatment planning device, comprising:

a treatment identifier (111) that identifies a set of treatments for the treatment plan based on the set of serum polypeptides.

21. The system of claim 20, wherein the set of treatments are identified before a radiotherapy treatment based on a predicted radiotoxicity of the patient based on the set of serum polypeptides.

22. The system of any of claims 20 to 21, wherein the set of serum polypeptides includes polypeptides with masses from a group consisting of 11,668 +23Da, 2,876 +6 Da, 6,432 +13 Da, 9,125 +18 Da, 2,220 +4 Da, 9,414 +19 Da and 14,571 +29 Da.

23. The system of any of claims 20 to 22, wherein the set of treatments are identified after at least one radiotherapy treatment based on a monitored radiotoxicity of the patient based on the set of serum polypeptides.

24. The system of any of claims 19 to 23, wherein the treatment planning device conveys the treatment plan to a therapy treatment system which automatically loads the treatment plan into the therapy treatment system.

25. The system of any of claims 19 to 23, wherein the treatment planning device visually presents the identified set of treatments.

26. The system of claim 25, wherein a risk of radiotoxicity is visually highlighted in the visually presented information.

27. The system of any of claims 25 to 26, wherein a visual presentation includes a risk toxicity index for the patient.

28. The system of any of claims 25 to 27, the treatment planning device, comprising: an optimizer (113) that optimizes treatment parameters of treatments in the treatment plan.

29. The system of any of claims 20 to 28, wherein the treatment planning device additionally utilizes one or more of imaging data, non-imaging data, and simulation data to create or adapt the treatment plan.

30. A computer readable storage medium encoded with computer readable instructions, which, when executed by a processor of a computing system, causes the system to: receive information about a polypeptide of a patient that indicates a radiotoxicity of the patient to radiotherapy treatment and create or adapt a treatment plan for the patient based on the received information, wherein the information includes at least a mass of the polypeptide and an intensity peak of the polypeptide.